Clinical study of lurasidone combined with SSRIs in the treatment of refractory obsessive-compulsive disorder

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086634

Enrollment

Unknown

Registered

2024-07-08

Start date

2024-07-08

Completion date

Unknown

Last updated

2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder

Interventions

Experimental group:Lurasidone (40-80 mg) combined with SSRIs was given for 8 weeks

Control group:Use SSRIs alone, adjust the dose based on the original drug, or change to another SSRIs, continuous treatment for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: On the basis of meeting the diagnostic criteria of ICD-10, the evaluation score of Yale-Brown obsessive compulsive scale (Y-BOCS) at enrollment was =16 points. The patient had a history of SSRIs anti-compulsive drug treatment with two or more types of drugs, no significant effect or even no effect, and the duration of treatment was greater than 12 weeks.

Exclusion criteria

Exclusion criteria: ?A clear history of psychosis or substance abuse; ?Patients with severe physical diseases or organic diseases of liver, kidney and brain, epilepsy, craniocerebral injury and severe neurological diseases; ? Patients with schizophrenia and affective disorder; ? Women who are pregnant or breastfeeding.

Design outcomes

Primary

Measure	Time frame
Yale-brown Compulsion Scale;Hamilton Anxiety Scale;Hamilton Depression Scale;Montreal Cognitive Assessment Scale;	—

Countries

Chnia

Contacts

Public ContactCong Weidong

Fuzhou Neuropsychiatric Hospital Affiliated to Fujian Medical University

congweidong@fjmu.edu.cn+86 139 0690 7704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026